
PRA Health Sciences, Inc. Financial Statements 2011-2025 | PRAH
Annual Financial Statements PRA Health Sciences, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
7.87 B | 6.53 B | 6.72 B | 5.73 B | 3.44 B | 2.58 B | 1.12 B | - | - | - |
Shares |
63.8 M | 64.5 M | 64.1 M | 62.4 M | 60.8 M | 60 M | 42.9 M | - | - | - |
Net Income |
197 M | 243 M | 154 M | 86.9 M | 68.2 M | 81.8 M | -35.7 M | - | -2.71 M | - |
Revenue |
3.18 B | 3.07 B | 2.87 B | 2.26 B | 1.81 B | 1.61 B | 1.46 B | - | 700 M | - |
EBITDA |
416 M | 482 M | 429 M | 343 M | 277 M | 243 M | 153 M | - | 77.9 M | - |
Operating Expenses |
585 M | 510 M | 484 M | 400 M | 339 M | 324 M | 351 M | - | 191 M | - |
General and Administrative Expenses |
453 M | 395 M | 372 M | 322 M | 270 M | 246 M | - | - | - | - |
All numbers in USD currency
Main types of financial statements PRA Health Sciences, Inc. PRAHFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting PRA Health Sciences, Inc. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
$ 0.33 | -6.23 % | $ 30.6 M | ||
|
Fluidigm Corporation
FLDM
|
$ 3.75 | 1.08 % | $ 308 M | ||
|
Global Cord Blood Corporation
CO
|
$ 2.99 | - | $ 399 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
$ 21.99 | - | $ 562 M | ||
|
Genetron Holdings Limited
GTH
|
$ 4.03 | 0.12 % | $ 80.1 M | ||
|
Chembio Diagnostics
CEMI
|
$ 0.46 | 0.22 % | $ 16.8 M | ||
|
Meridian Bioscience
VIVO
|
$ 33.97 | - | $ 1.49 B | ||
|
HTG Molecular Diagnostics
HTGM
|
$ 0.48 | -20.0 % | $ 1.06 M | ||
|
Neogen Corporation
NEOG
|
$ 5.92 | -4.67 % | $ 1.28 B | ||
|
Quotient Limited
QTNT
|
$ 0.32 | -11.32 % | $ 1.1 M | ||
|
Pacific Biosciences of California
PACB
|
$ 1.85 | -3.4 % | $ 469 M | ||
|
Bioventus
BVS
|
$ 7.42 | 0.54 % | $ 465 M | ||
|
Heska Corporation
HSKA
|
$ 119.99 | - | $ 1.31 B | ||
|
Motus GI Holdings
MOTS
|
$ 0.17 | -34.28 % | $ 263 K | ||
|
Biocept
BIOC
|
$ 0.43 | -13.05 % | $ 7.29 M | ||
|
Thermo Fisher Scientific
TMO
|
$ 565.62 | -0.38 % | $ 216 B | ||
|
Syneos Health
SYNH
|
$ 42.98 | - | $ 4.46 B | ||
|
Trinity Biotech plc
TRIB
|
$ 1.0 | 0.49 % | $ 61.9 M | ||
|
Invitae Corporation
NVTA
|
$ 0.09 | - | $ 21.2 M | ||
|
DermTech
DMTK
|
$ 0.09 | -11.32 % | $ 2.94 M | ||
|
Akumin
AKU
|
$ 0.29 | -17.87 % | $ 25.9 M | ||
|
Twist Bioscience Corporation
TWST
|
$ 30.2 | -4.19 % | $ 1.75 B | ||
|
Castle Biosciences
CSTL
|
$ 33.8 | 0.69 % | $ 939 M | ||
|
DarioHealth Corp.
DRIO
|
$ 12.58 | -7.4 % | $ 357 M | ||
|
PerkinElmer
PKI
|
$ 115.24 | -0.91 % | $ 14.7 B | ||
|
OpGen
OPGN
|
$ 1.96 | -16.95 % | $ 1.54 M | ||
|
DexCom
DXCM
|
$ 57.98 | -2.19 % | $ 22.4 B | ||
|
Organovo Holdings
ONVO
|
$ 2.12 | -2.3 % | $ 19.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 12.38 | 1.43 % | $ 132 M | ||
|
Koninklijke Philips N.V.
PHG
|
$ 28.25 | 0.61 % | $ 20 B | ||
|
Danaher Corporation
DHR
|
$ 211.09 | -0.57 % | $ 154 B | ||
|
Biomerica
BMRA
|
$ 2.55 | -1.16 % | $ 5.86 M | ||
|
Fulgent Genetics
FLGT
|
$ 22.3 | -2.11 % | $ 674 M | ||
|
Psychemedics Corporation
PMD
|
$ 2.67 | -1.84 % | $ 15.3 M | ||
|
Genetic Technologies Limited
GENE
|
$ 0.77 | - | $ 7.1 B | ||
|
Renalytix AI plc
RNLX
|
$ 0.21 | 5.66 % | $ 22.7 M | ||
|
Myriad Genetics
MYGN
|
$ 6.32 | -4.03 % | $ 573 M | ||
|
Quidel Corporation
QDEL
|
$ 21.96 | -19.78 % | $ 925 M | ||
|
Medpace Holdings
MEDP
|
$ 596.05 | -0.46 % | $ 18.5 B | ||
|
IQVIA Holdings
IQV
|
$ 211.48 | 0.67 % | $ 38.3 B | ||
|
Exagen
XGN
|
$ 10.74 | 3.97 % | $ 190 M | ||
|
CareDx, Inc
CDNA
|
$ 14.79 | -10.53 % | $ 795 M | ||
|
Brainsway Ltd.
BWAY
|
$ 15.74 | -2.69 % | $ 99.4 M | ||
|
Biodesix
BDSX
|
$ 8.28 | -3.78 % | $ 1.07 B | ||
|
T2 Biosystems
TTOO
|
$ 0.12 | -39.35 % | $ 313 K | ||
|
OPKO Health
OPK
|
$ 1.38 | 2.61 % | $ 958 M | ||
|
Guardant Health
GH
|
$ 96.79 | 1.83 % | $ 11.9 B | ||
|
Agilent Technologies
A
|
$ 147.11 | 0.22 % | $ 44.7 B | ||
|
Co-Diagnostics
CODX
|
$ 0.39 | -0.51 % | $ 11.4 M |